26 results about "Platinum Compound" patented technology

The invention belongs to the technical field of medicine synthesis, and particularly relates to a tetravalent platinum compound as well as a preparation method and application thereof. The invention provides a tetravalent platinum compound. The tetravalent platinum compound has a structure shown as a formula a to a formula d, wherein linker is respectively connected with a Pt-containing mother nucleus and a PARP inhibitor through-O-C = O; the PARP inhibitor comprises a carboxyl-containing structure and a carboxyl-free structure; when the PARP inhibitor contains a carboxyl structure, the linker is when the PARP inhibitor does not contain the carboxyl structure, and the data of the linker as the embodiment shows that the tetravalent platinum compound provided by the invention has good anti-tumor activity and low tumor drug resistance when being used as the PARP inhibitor.

The application discloses a phosphorescent dopant material of a platinum compound, a preparation method, an organic electroluminescent device and application, the phosphorescent dopant material is a platinum compound with a structure shown in chemical formula I, the compound introduces a bicyclic structure on the basis of a parent nucleus, a high conjugated electron distribution system, so that the electron distribution and the excited state can be controlled, and the stability of the material is enhanced. The organic electroluminescent device prepared by adopting the compound as a light-emitting layer dopant material has high luminous efficiency, long service life and the technical effect of improving the driving voltage.

The present invention provides a derivative having a desloratadine tetravalent platinum structure, a preparation method, and a use thereof. The compound having a desloratadine tetravalent platinum structure is shown in general formula (I), #imgabs0# wherein #imgabs1# is selected from cisplatin or oxaliplatin; L is hydroxyl or #imgabs2#. The desloratadine tetravalent platinum compound of the present invention has good anti-tumor proliferation activity and a good therapeutic effect on metastatic malignant tumors; it can effectively inhibit the tumor epithelial-mesenchymal transition (EMT) process and effectively activate tumor immune response, and can be used to prepare anti-tumor drugs, especially providing a new direction for the research and development of anti-metastatic malignant tumor drugs.

The invention relates to a method for producing trimethylplatinum(IV) iodide and trimethylplatinum(IV) iodide obtainable according to said method and the use thereof as a reactant for producing platinum(IV) compounds, as a precatalyst and as a catalyst. The platinum(IV) compounds thus obtainable, as well as the use thereof as precursors for the deposition of platinum layers and platinum-containing layers on a surface of a substrate are also the subject matter of the invention. The invention also relates to a substrate comprising a platinum layer or a platinum-containing layer on a surface, and to a method for producing an electronic component, in particular an electronic semiconductor component, or an electrode for a fuel cell using a platinum(IV) compound obtainable using trimethylplatinum(IV) iodide, which is obtainable by means of the method described herein.

The invention relates to a method for producing trimethylplatinum(IV) iodide and trimethylplatinum(IV) iodide obtainable according to said method and the use thereof as a reactant for producing platinum(IV) compounds, as a precatalyst and as a catalyst. The platinum(IV) compounds thus obtainable, as well as the use thereof as precursors for the deposition of platinum layers and platinum-containing layers on a surface of a substrate are also the subject matter of the invention. The invention also relates to a substrate comprising a platinum layer or a platinum-containing layer on a surface, and to a method for producing an electronic component, in particular an electronic semiconductor component, or an electrode for a fuel cell using a platinum(IV) compound obtainable using trimethylplatinum(IV) iodide, which is obtainable by means of the method described herein.

The invention relates to a pegylated cis-platinum compound as well as a preparation method and application thereof, and belongs to the technical field of drug carriers. The pegylated cis-platinum compound is obtained through covalent coupling of polyethylene glycol and cis-platinum. The invention provides a novel pegylated cis-platinum compound and a preparation method thereof, a pharmaceutical composition containing the pegylated cis-platinum compound and a preparation of the pharmaceutical composition, and particularly relates to a nucleic acid pharmaceutical composition containing the pegylated cis-platinum compound and a preparation of the nucleic acid pharmaceutical composition. The nucleic acid medicine composition preparation can deliver the nucleic acid medicine into cells, the transport rate of the nucleic acid medicine is increased, toxicity is reduced, and therefore the treatment effect of the nucleic acid medicine is improved.

To provide a drug-induced renal dysfunction relieving agent that enables inhibition or mitigation of renal dysfunction resulting from administration of a drug.SOLUTION: A drug-induced renal dysfunction relieving agent comprising, as an active ingredient, a dopamine D2-like receptor agonist. The dopamine D2-like receptor may be DRD2. The dopamine D2-like receptor agonist may be at least one selected from the group consisting of quinpirole, dopamine, ropinirole, and bromocriptine. The agent is preferably administered to a patient having drug-induced renal dysfunction caused by administration of a platinum-based anticancer agent, an antibacterial agent, an antiviral agent, a contrast medium, or an NSAIDs.SELECTED DRAWING: None

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotope variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof, and a pharmaceutical composition comprising same and a use thereof as a radiosensitizing drug.

The invention discloses a polygonal anthracene functionalized BODIPY supramolecular metal ring compound as well as a preparation method and application thereof, and belongs to the technical field of supramolecular materials, the polygonal anthracene functionalized BODIPY supramolecular metal ring compound is obtained by self-assembly reaction of an anthracene functionalized BODIPY photosensitizer with a specific structure and a platinum compound; by selecting platinum compounds with different coordination included angles, triangular, quadrilateral and hexagonal supramolecular metal ring compounds are respectively prepared. Furthermore, amphiphilic polymer F127 is used for wrapping the supramolecular metal ring compound to form water-soluble nanoparticles, so that phototherapy and chemotherapy combined therapy of hypoxic tumors can be realized, and the amphiphilic polymer F127 has a wide application prospect in the aspects of biological imaging and tumor therapy.

The application provides a trifunctional tetravalent platinum compound of captopril-aspirin ligand and a reference drug of a bifunctional tetravalent platinum compound of captopril; and develops a nanomedicine Tf-GEVs@Pt(IV) of the aspirin-captopril trifunctional tetravalent platinum compound loaded in grapefruit extracellular vesicles (GEVs). The Tf-GEVs@Pt(IV) is prepared from the trifunctional tetravalent platinum compound as an active ingredient, the carrier grapefruit extracellular vesicles (GEVs), the carrier DSPE-PEG and the transferrin modified targeting carrier DSPE-PEG-Tf. The Tf-GEVs@Pt(IV) can release the active component trifunctional tetravalent platinum compound in vivo. In addition to causing DNA damage, the trifunctional tetravalent platinum compound as the active component of the nanomedicine can effectively regulate inflammatory, fibrotic and immunosuppressive TME. The nanomedicine has a significant anti-tumor ability and has excellent therapeutic effect on metastatic malignant tumors, and is expected to provide a new candidate drug for clinical treatment of tumors and provide a new direction for research and development of new platinum drugs and anti-metastatic malignant tumor drugs.

This invention belongs to the field of silicone rubber technology and relates to a flame-retardant compounded silicone rubber and its preparation method. The invention involves first adding methyl vinyl silicone rubber raw material, precipitated silica, hydroxyl silicone oil, zinc stearate, silane coupling agent, and composite flame-retardant filler to a kneader for kneading. After kneading, heat treatment, and cooling, compound A is obtained. Then, compound A is mixed evenly with a platinum-containing flame-retardant additive in a specific ratio on a two-roll mill to obtain the flame-retardant compounded silicone rubber. The platinum-containing flame-retardant additive is a compound of platinum compound and vinyl amino silicone oil at a mass ratio of 1:0.5~1. This method is simple, and the prepared compounded silicone rubber has high flame-retardant properties. It utilizes a combination of platinum compound, nitrogen-containing organic compound, and composite flame-retardant filler, resulting in a strong synergistic flame-retardant effect. It also offers advantages such as good roller workability, high processing efficiency, and minimal yellowing of vulcanized samples, making it easy to promote and apply.

The invention discloses a high-thermal-conductivity flame-retardant organic silicon pouring sealant for a power battery module as well as a preparation method and application of the high-thermal-conductivity flame-retardant organic silicon pouring sealant. The pouring sealant is composed of a component A and a component B, wherein the component A contains vinyl-terminated polysiloxane, a composite heat-conducting filler, a synergistic flame retardant, a cross-linking agent and an inhibitor; and the component B contains vinyl-terminated polysiloxane, a composite heat-conducting filler, a synergistic flame retardant and a platinum catalyst. The composite heat-conducting filler is prepared from modified spherical aluminum oxide and flaky boron nitride according to a specific proportion, and the synergistic flame retardant is prepared by compounding encapsulated red phosphorus and a platinum compound. The component A and the component B are mixed according to the ratio of 1: 1 and then cured to form the elastomer with high thermal conductivity (greater than or equal to 2.0 W / m.K), high flame retardance (UL94 V-0), low stress and high reliability. The pouring sealant disclosed by the invention is particularly suitable for a power battery module needing efficient heat management and extreme safety.

The invention provides a glycyrrhetinic acid-platinum compound as shown in a structural formula as well as a preparation method and application thereof, and belongs to the technical field of medicines. The preparation method comprises the following steps: taking glycyrrhetinic acid as a raw material, coupling the glycyrrhetinic acid with dimethyl 3-amino-1, 1-cyclobutanedicarboxylate through an amido bond, converting the glycyrrhetinic acid into a sodium salt, and carrying out coordination substitution reaction on the sodium salt and a hydrate cis-[PtA2 (H2O) 2] (NO3) 2 of a platinum drug on the market to prepare a compound 1; the compound provided by the invention has inhibitory activity on human hepatoma cell lines HepG2, Huh7 and SK-Hep-1, can form a pharmaceutical composition with a pharmaceutically acceptable carrier, and can be used for preparing anti-hepatoma drugs.

The invention belongs to the technical field of biological medicines, and discloses an oxaprozin coupled cis-platinum compound as well as a preparation method and application thereof. The oxaprozin coupled cis-platinum compound disclosed by the invention is tetravalent platinum prepared by coupling cis-platinum and oxaprozin which is a drug with carboxyl; the oxaprozin coupled cis-platinum compound disclosed by the invention can improve the toxic and side effects of cis-platinum and increase novel axial functional groups, and has the technical advantages of excellent anti-tumor activity, stability, safety and low cost.

The present invention discloses a tetravalent platinum complex containing APR-246, having a structure as shown in Formula I: wherein n is selected from 0, 1, 2, 3, or 4; R is selected from a branched or linear C1-C20 alkyl group; and R2 is selected from a branched or linear C1-C20 alkyl group. The tetravalent platinum compounds containing the p53 mutation activator APR-246 provided by the present invention can enhance the anti-tumor activity of APR-246 and leverage the anti-tumor advantages of APR-246 and divalent platinum drugs. By utilizing the unique anti-tumor mechanism of APR-246, they can work together with platinum drugs to achieve excellent synergistic anti-tumor efficacy, while also significantly helping to improve tumor drug resistance.

The invention belongs to the technical field of medicinal chemistry, and particularly discloses a platinum (IV) prodrug with ferroptosis and apoptosis induction effects as well as a preparation method and application of the platinum (IV) prodrug. According to the invention, a novel platinum (IV) compound with a ferroptosis induction effect is developed based on platinum (IV) prodrugs of salazosulfapyridine, cis-platinum and carboplatin; the platinum (IV) prodrug disclosed by the invention shows excellent anti-proliferative activity to cisplatin-sensitive and drug-resistant triple negative breast cancer cells, and compared with cisplatin, the platinum (IV) prodrug has lower activity to a normal mammary gland cell line (MCF-10A). Accumulation of reactive oxygen species (ROS) in cells can be improved by inducing DNA damage, and a mitochondrial dependent approach is activated to induce apoptosis. Meanwhile, accumulation of lipid peroxide can be remarkably promoted, xCT and GPX4 levels are reduced, and mitochondrial morphological change is induced to stimulate ferroptosis; in vivo, the cis-platinum (IV) prodrug shows strong anti-tumor activity in an MDA-MB-231 / CDDP xenograft model, and the cis-platinum (IV) prodrug has strong anti-tumor activity; the platinum (IV) prodrug has a potential application prospect in targeted therapy of triple negative breast cancer.

We provide a silicone rubber that is biocompatible with the human body and can be manufactured at a lower cost than conventional methods. [Solution] The silicone admixture according to the present invention comprises a casting-type silicone rubber, a vulcanizing agent, and a silicone polymer without crosslinking sites, and can become a cured product with a loss tangent (Tanδ) of 0.2 or more at 10°C to 40°C. The casting-type silicone rubber is a liquid silicone rubber that can be cured by addition reaction, and the vulcanizing agent is a platinum compound. The silicone polymer without crosslinking sites is a dimethyl silicone polymer.

The application discloses a fireproof and flame-retardant coating, which comprises, in parts by weight, 80-100 parts of organic silicon modified water-based polyurethane, 2-5 parts of zirconium phosphate-platinum catalyst, 5-10 parts of mica powder and 5-10 parts of silicon dioxide. The application further discloses a preparation method of the fireproof and flame-retardant coating. The fireproof and flame-retardant coating has the characteristics of low surface energy, fireproof and flame-retardant due to the low surface energy of organic silicon, the introduction of silicon into the polyurethane base material, the catalytic effect of ZrP-Pt, the catalytic characteristics of zirconium phosphate, the porcelain characteristics of platinum, the interlayer structure of zirconium phosphate, the solidification of platinum compounds, the introduction of phosphorus elements, the carbon change of organic matter into amorphous carbon, the formation of a carbon layer, the support of the mica powder, the maintenance of the integrity of the ceramic structure and the synergistic effect of the coating.

The present invention provides a compound of formula (I), or a pharmaceutically acceptable salt, isotope variant, tautomer, stereoisomer, prodrug, polymorph, hydrate, or solvate thereof, and a pharmaceutical composition comprising same and a use thereof as a radiosensitizing drug.

In the present invention, a block copolymer containing a biocompatible polymer block and a polyamino acid block, and a micelle containing an oxidized platinum compound exhibit significantly lower distribution of platinum to bone marrow than a reduced platinum compound. In other words, myelosuppression, which is one side effect, can be prevented, and thus white blood cell production is not inhibited. Further, by using the micelle and an immune checkpoint inhibitor in combination, the activity of T cells, which are a type of white blood cells, is maintained, and thus a drug combining the two is useful in the treatment and / or prevention of cancer.

The invention belongs to the technical field of hydrogen evolution electrodes, and provides a hydrogen evolution cathode and a preparation method and application thereof. The preparation method comprises the following steps: repeatedly and sequentially coating a catalyst solution system and sintering on a nickel substrate to obtain a precursor; and placing the precursor in an inorganic alkali solution for electric activation to obtain the hydrogen evolution cathode, the catalyst solution system comprises a catalytic metal compound, hydrochloric acid and a solvent; the catalytic metal compound comprises one or more of a nickel compound, a cerium compound, a ruthenium compound, a molybdenum compound, a platinum compound and an iron compound; the sintering temperature independently ranges from 400 DEG C to 600 DEG C, the sintering time independently ranges from 10 min to 60 min, and the sintering atmosphere is air. According to the invention, the hydrogen evolution cathode with a composite nano structure is obtained on a nickel substrate through coating, sintering and electric activation. According to the prepared hydrogen evolution cathode, the binding force between the catalyst layer and the nickel substrate is high, and the service life is prolonged.

Provided is a calcined body that generates photons. The calcined body of the present invention is a calcined body of a composition comprising: (i) alumina; (ii) at least one selected from the group consisting of silica and titanium oxide; (iii) at least one selected from the group consisting of platinum, platinum compounds, palladium, palladium compounds, iridium, iridium compounds, rhodium, and rhodium compounds; and (iv) silicon nitride, in 100 parts by mass of the composition, 5-10 parts by mass of the (iv) silicon nitride is contained.

The present invention relates to novel EGFR inhibitor-functionalized albumin-binding platinum compounds of formula (I), including in particular EGFR inhibitor-functionalized albumin-binding oxaliplatin and carboplatin derivatives, as well as their use in therapy, particularly for the treatment or prevention of cancer. (Formula (I))

Methods are provided for treating cancers characterized by chondroitin sulfate (CS) expression, particularly chondroitin-4- sulfate (C4S) using polynuclear platinum compounds such as Triplatin tetranitrate. The methods include detecting CS levels in tumor tissue, selecting subjects with elevated CS, and administering an effective amount of the compound to treat cancer. Improved therapeutic selectivity and outcomes are achieved in tumors exhibiting CS enrichment.

It is an object of the present invention to provide a silicone rubber that can be produced at a lower cost than before and is compatible with human bodies. The silicone admixture according to the present invention contains a castable silicone rubber, a vulcanizing agent, and a silicone high polymer having no cross-linking site and is capable of becoming a cure product having loss tangent (tan δ) of 0.2 or more at 10° C. to 40° C. The castable silicone rubber is a liquid silicone rubber that is curable by addition reaction, and the vulcanizing agent is a platinum compound. The silicone high polymer having no cross-linking site is a dimethyl silicone high polymer.